Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus - Infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1126-1132

  Kaplan, Jonathan E ^a   Hanson, Debra L ^b   Navin, Thomas R ^b   Jones, Jeffrey L ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ADOLESCENT; ADULT; ARTICLE; CHEMOPROPHYLAXIS; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; THRUSH; TREATMENT INDICATION; UNITED STATES;

EID: 0031686771     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515658     Document Type: Article

References (5)

1. Centers for Disease Control. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.
2. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. Clin Infect Dis 1995;21(suppl 1):S1-11.
3. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989;38(S-5):1-9.
4. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997;46(RR-12):1-46.
5. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992;267:1798-805.